Germline DNA samples from African American women from 10 U.S. studies were tested for mutations in 20 established breast cancer predisposition genes using a QIAseq multiplex amplicon panel as part of the Cancer Risk Estimates...
Read MoreImmunotherapy (IO) + chemotherapy ± anti-angiogenics comprise FDA-approved 1L regimens for metastatic non-small cell lung cancer (NSCLC), with IO-only therapy approved only for PD-L1+ NSCLC. Patients with PD-L1 scores from...
Read MoreSurvival outcomes for patients with adenosquamous carcinoma of the lung are not well understood by virtue of reduced prevalence. To address this, a recent study sought to compare the long-term survival among patients with...
Read MoreTrastuzumab based regimen was the most common anti-HER2 drug regimen during study timeframe. Despite availability of multiple anti-HER2 drugs, reuse of prior anti-HER2 drugs and switching to non-targeted therapies alone were...
Read MoreTesting for mutations in BRCA1 and BRCA2 is recommended for all women with ovarian cancer, given important implications for treatment and prognosis. Despite this recommendation, studies show that only a small percentage of...
Read MoreAlthough ovarian cancer is the third most common Lynch syndrome (LS)-associated cancer in women, there is no established screening strategy to identify LS in this population. It is hypothesized that an adequate family history...
Read MoreDisparities in the adherence to National Comprehensive Cancer Network (NCCN) guideline-directed treatment and socioeconomic characteristics may be responsible for the differences in ovarian cancer outcomes of ovarian cancer in...
Read MoreThe National Cancer Institute (NCI) Framework for patient-centered communication (PCC) in Cancer Care highlights the potential of PCC to improve health-related quality of life (HRQoL), but to date, few studies have empirically...
Read MoreDespite higher rates of diabetes (DM), hypertension (HTN), and hyperlipidemia (HLD) with increasing body mass index (BMI), a diagnosis of obesity was not associated with worse overall survival (OS) in women with breast cancer...
Read MoreThe relationship between treatment intensity and characteristics of patients with early-stage breast cancer. Differences in treatment intensity were observed for patients with differing demographic characteristics. Further...
Read More
Overall survival and progression-free survival enhanced with 177Lu-PSMA-617 A novel agent that...
Read More
Patients receiving chemotherapy for breast cancer do not have an increased risk for severe acute...
Read MoreThe ASCO Annual Meeting enters its second year in a virtual setting June 4-8, 2021, to ensure the safety and health of attendees while delivering groundbreaking science in oncology and timely information on clinical application...
Read MoreThe ASCO Annual Meeting enters its second year in a virtual setting June 4-8, 2021, to ensure the safety and health of attendees while delivering groundbreaking science in oncology and timely information on clinical application...
Read MoreThe ASCO Annual Meeting enters its second year in a virtual setting June 4-8, 2021, to ensure the safety and health of attendees while delivering groundbreaking science in oncology and timely information on clinical application...
Read More
TUESDAY, June 1, 2021 (HealthDay News) – Oncologists may substantially underestimate how many...
Read MoreAlthough assessing and reducing the severity of tardive dyskinesia (TD)—a persistent and potentially disabling movement disorder linked with exposure to antipsychotics and other dopamine receptor blocking agents—is crucial for...
Read More
New research was virtually presented at AACR 2021, the American Association for Cancer Research...
Read MoreBy: Cecilia Peterson; Amanda Glazar; Chirag Shah; Prakash Masand; Michael Lemon Introduction: Tardive Dyskinesia (TD) refers to abnormal, involuntary, choreoathetoid movements of the tongue, lips, face, trunk, and extremities...
Read MorePlasma neurofilament light chain (NfL) demonstrated to be a more valuable biomarker for neurodegeneration than total tau (T-tau) protein. This was the conclusion of the Mayo Clinic Study of Aging (MCSA), comparing the 2...
Read More
